Anika Therapeutics | ANIK - Interest Expense On Debt


Anika Therapeutics reported 183.47M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Abbott USD 299M 231M Jun/2026
Agenus USD 14.67M 1.35M Mar/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 18.84M 1.24M Jun/2026
Integra LifeSciences USD 22.99M 529K Jun/2026
Intrexon USD 2K 5K Jun/2024
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
Merit Medical Systems USD 12.12M 5.59M Jun/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Smith & Nephew USD 69M 1000K Dec/2025
Stryker USD 47.93B 1.64B Jun/2026
Veracyte USD 2K 1000 Dec/2023
Xencor USD 7.35M 2.65M Jun/2026
Zimmer Biomet Holdings USD 22.8B 22.73B Jun/2026